Privately-held Dutch immune-mediated inflammatory diseases company Citryll is the latest stop for experienced biotech chief executive Eduardo Bravo.
Mr Bravo has previously held the top job at Nordic Nanovector, TiGenix and Cellerix. During his time at TiGenix, he led the company through several successful financing rounds, facilitated its IPO on Nasdaq, and ultimately oversaw its acquisition by Japanese pharma major Takeda (TYO: 4502).
Most recently, Mr Bravo was the chief executive of EBAC, an EQT-backed special acquisition company that successfully merged with the clinical-stage Swiss biotech Oculis (Nasdaq: OCS) in March.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze